Findings

What do systematic reviews say?

17 questions · 17 findings · 8 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 17.6%GRADE not reported 1 · 5.9%Very low 1 · 5.9%Low 2 · 11.8%Moderate 8 · 47.1%High 2 · 11.8%

Aromatherapy vs placebo or control

Activities of daily living · people with dementia

1 finding from 1 review

Aromatherapy for dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 91 participants
Very low

Other NSAIDs vs placebo

Activities of daily living · cognitively healthy people in late life

The review found no eligible studies for this question.

1 finding from 1 review

Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Celecoxib vs placebo

Activities of daily living · older people with age‐related memory loss

The review found no eligible studies for this question.

1 finding from 1 review

Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs placebo

Activities of daily living · cognitively healthy people in late life

Aspirin showed no clear difference in activities of daily living compared with placebo (high certainty).

1 finding from 1 review

Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia 2020 · Cochrane Headline outcomes only
RR 0.84 [0.7, 1.02]
1 study · 19114 participants
High

Souvenaid vs placebo

Functional outcomes · People with mild Alzheimer's disease

1 finding from 1 review

Souvenaid for Alzheimer's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 259 participants
Moderate

Souvenaid vs placebo

Activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Souvenaid for Alzheimer's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 527 participants
Moderate

Souvenaid vs placebo

Functional outcomes · People with MCI/prodromal AD

1 finding from 1 review

Souvenaid for Alzheimer's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Antidepressants vs placebo

Activities of daily living · patients with depression and dementia

1 finding from 1 review

Antidepressants for treating depression in dementia 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 173 participants
High

Galantamine vs placebo

Functional performance and activities of daily living at 26 weeks ADCS‐ADL and DAD · vascular dementia and other vascular cognitive impairments

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1174 participants
Low

Donepezil 10 mg/day vs placebo

Change in capacity for activities of daily living · people with severe Alzheimer's disease

1 finding from 1 review

Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 733 participants
Moderate

Donepezil 10 mg/day vs placebo

Change in capacity for activities of daily living · people with Alzheimer's disease

1 finding from 1 review

Donepezil for dementia due to Alzheimer's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 733 participants
Moderate

Rivastigmine vs placebo

Change in capacity for activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease

1 finding from 1 review

Rivastigmine for Alzheimer's disease 2015 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 3230 participants
Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Activities of daily living · people with Alzheimer's disease

1 finding from 1 review

Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 280 participants
Moderate

Rivastigmine vs placebo

Functional ability: independence with activities of daily living at discharge from hospital · vascular dementia and other vascular cognitive impairments

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 800 participants
Low

Donepezil 5 mg vs placebo

Functional outcomes · vascular dementia and other vascular cognitive impairments

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 798 participants
Moderate

Donepezil 10 mg/day vs placebo

Functional outcomes · vascular dementia and other vascular cognitive impairments

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 813 participants
Moderate

Vitamin E (capsules 2000 IU/day in two divided doses) vs placebo

Activities of daily living · MCI

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin E for Alzheimer's dementia and mild cognitive impairment 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found